Chimeric Antigen Receptor-T Cell (CAR-T) therapy is a cell-based gene therapy designed to attack cancer cell antigens, specifically in patients with relapsed/refractory (R/R) B-cell malignancies. To date, six CAR-T therapies have been approved by the European Medicines Agency (EMA) across different indications.
This poster, presented at ISPOR 2023, examined the time to approval for six CAR-T therapies in four Nordic countries (Denmark, Finland, Norway and Sweden), after authorization by the EMA.
